Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Utah Medical Products Inc (UTMD)
Price$71.10Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38.5M | $40.9M | $50.2M | $52.3M | $49.1M | $42.2M | $46.9M | $42.0M | $41.4M | $39.3M | $40.2M | $41.3M | $40.5M | $41.6M | $37.9M | $25.1M | $25.9M |
| Gross profit | $22.0M | $24.1M | $30.0M | $32.2M | $30.9M | $25.5M | $29.5M | $26.3M | $26.4M | $23.7M | $24.2M | $25.0M | $24.3M | $25.3M | $22.4M | $13.2M | $13.8M |
| Gross margin | 57.12% | 59.03% | 59.81% | 61.58% | 63.03% | 60.57% | 62.82% | 62.64% | 63.73% | 60.28% | 60.23% | 60.52% | 59.94% | 60.90% | 59.17% | 52.58% | 53.21% |
| Research & development | $668,000 | $813,000 | $560,000 | $493,000 | $526,000 | $486,000 | $483,000 | $454,000 | $447,000 | $475,000 | $522,000 | $460,000 | $491,000 | $563,000 | $518,000 | $397,000 | $361,000 |
| Operating expenses | $10.6M | $10.5M | $13.3M | $12.4M | $12.0M | $11.8M | $11.8M | $7.6M | $7.4M | $7.5M | $8.5M | $8.8M | $9.4M | $10.1M | $10.6M | $4.3M | $4.4M |
| Operating income | $11.4M | $13.6M | $16.8M | $19.8M | $18.9M | $13.7M | $17.6M | $18.7M | $19.0M | $16.2M | $15.7M | $16.2M | $14.8M | $15.2M | $11.8M | $8.9M | $9.4M |
| Operating margin | 29.60% | 33.23% | 33.40% | 37.85% | 38.49% | 32.50% | 37.59% | 44.52% | 45.90% | 41.19% | 38.97% | 39.25% | 36.62% | 36.57% | 31.28% | 35.52% | 36.39% |
| EBITDA | $14.4M | $16.4M | $23.1M | $26.8M | $26.2M | $20.9M | $24.5M | $19.5M | $19.7M | $16.8M | $16.3M | $16.8M | $15.4M | $15.8M | $12.5M | $9.5M | $10.0M |
| EBITDA margin | 37.26% | 40.07% | 45.98% | 51.30% | 53.33% | 49.50% | 52.18% | 46.34% | 47.50% | 42.74% | 40.52% | 40.79% | 38.13% | 38.14% | 33.15% | 37.76% | 38.54% |
| Net income | $11.3M | $13.9M | $16.6M | $16.5M | $14.8M | $10.8M | $14.7M | $18.6M | $8.5M | $12.1M | $11.8M | $11.4M | $11.4M | $10.2M | $7.4M | $6.0M | $6.3M |
| Net profit margin | 29.30% | 33.92% | 33.12% | 31.51% | 30.15% | 25.60% | 31.40% | 44.18% | 20.54% | 30.86% | 29.49% | 27.56% | 28.17% | 24.47% | 19.58% | 23.94% | 24.15% |
| Basic EPSper basic share | $3.48 | $3.96 | $4.58 | $4.53 | $4.05 | $2.95 | $3.96 | $4.97 | $2.29 | $3.23 | $3.16 | $3.04 | $3.06 | $2.77 | $2.04 | $1.66 | $1.73 |
| Diluted EPSper diluted share | $3.48 | $3.96 | $4.57 | $4.52 | $4.04 | $2.94 | $3.94 | $4.95 | $2.28 | $3.22 | $3.14 | $3.02 | $3.02 | $2.74 | $2.03 | $1.65 | $1.72 |
Owners
Reported shareholders
14.93%of listed shares
BRANDES INVESTMENT PARTNERS, LP475.16K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BRANDES INVESTMENT PARTNERS, LP | 14.93%475.16K shares |
BlackRock, Inc. | 6.40%203.69K shares |
DIMENSIONAL FUND ADVISORS LP | 6.25%198.82K shares |
RENAISSANCE TECHNOLOGIES LLC | 5.52%175.81K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.23%134.54K shares |
GEODE CAPITAL MANAGEMENT, LLC | 3.39%108.05K shares |
Minerva Advisors LLC | 2.94%93.62K shares |
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | 2.68%85.23K shares |
RICE HALL JAMES & ASSOCIATES, LLC | 2.24%71.36K shares |
MORGAN STANLEY | 2.19%69.67K shares |
STATE STREET CORP | 2.01%63.94K shares |
Quantinno Capital Management LP | 1.35%43.07K shares |
UBS Group AG | 1.08%34.37K shares |
Bank of New York Mellon Corp | 1.08%34.26K shares |
NORTHERN TRUST CORP | 0.95%30.1K shares |
Huber Capital Management LLC | 0.91%29.01K shares |
Cardinal Capital Management | 0.85%27.09K shares |
EVERETT HARRIS & CO /CA/ | 0.75%23.93K shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 0.69%21.94K shares |
O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 0.68%21.68K shares |
Percentages use 3.18M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
Community posts
Utah Medical launches $75-per-share self-tender offer
Utah Medical Products ($UTMD) commenced a tender offer to repurchase up to 650,000 common shares at $75 each. At full acceptance, the share purchase would total $48.75 million before related costs. The offer follows previously announced ter ...
